IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
Innoviva, Inc. (INVA) is a healthcare royalty company. Its primary asset is a significant royalty stake in several major respiratory drugs developed in partnership with GSK (GlaxoSmithKline), including the blockbuster TRELEGY.
Investment Thesis
Innoviva is a 'pure-play' cash machine. Unlike traditional biotech companies that burn through cash on R&D, Innoviva's primary job is to collect and distribute royalties from some of the most successful respiratory drugs in history. Because these drugs are critical for millions of COPD and asthma patients, the cash flows are incredibly stable and inflation-resistant. Management is using this recurring windfall to aggressively buy back stock and selectively invest in other high-potential healthcare royalties. It is essentially a high-yield, high-margin healthcare bond with significant upside from drug sales growth.
Key Growth Drivers
Blockbuster Respiratory Royalties
The continued market share gains of TRELEGY ELLIPTA provide Innoviva with a massive, high-margin revenue stream that is guaranteed for years to come.
Asset-Light Model
Innoviva operates with a tiny headcount and almost zero CapEx, resulting in nearly 100% of its operating revenue flowing directly to free cash flow.
Aggressive Float Reduction
The company has utilized its cash to retire a staggering amount of its own shares, dramatically increasing the ownership stake and earnings power of the remaining shareholders.
Valuation & Financial Modeling
INVA trades at a low single-digit multiple of its free cash flow, a valuation that is typically reserved for companies in terminal decline. We view this as a severe mispricing of a high-quality, long-dated royalty asset. The market is ignoring the longevity of its core respiratory franchise.
Risk Factors & Bear Case
The primary risk is the eventual patent expiration of its core drugs, which will lead to a gradual decline in royalty revenue. Furthermore, any strategic missteps in their reinvestment of cash into new, unproven biotech assets could destroy shareholder value.
Conclusion
Innoviva is an elite income-generating asset. It offers an irreplaceable royalty stream and a masterclass in shareholder yield. Rated 'Strong Buy'.
Upcoming Catalysts
No upcoming catalysts identified.
Unlock Investment Thesis
Sign up for free access to institutional-quality research tools.
Relative valuation derived from Healthcare sector median benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Multiples adjusted for extreme outliers and non-recurring volatility.
Auditing capital efficiency...
Quality Profile Audit
Score: 50GRADE C+
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation.
Return on Equity
Profit generated per dollar of shareholder equity
9.2%
Sector: -43.5%
Dividend Analysis audit
No Dividend
This company does not currently pay a dividend.
Analyst Projections
Analyst Consensus
Unlock Valuation Tools
Sign up for free access to institutional-quality research tools.
Based on our 6-factor quantitative model, Innoviva, Inc. (INVA) receives a "Hold" rating with a composite score of 52.7/100, ranked #185 out of 4446 stocks. Key factor scores: Quality 50/100, Value 72/100, Momentum 60/100. This is quantitative analysis only — not investment advice.
Innoviva, Inc. (INVA) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Innoviva, Inc. Do?
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. Innoviva, Inc. (INVA) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Pavel Raifeld and employs approximately 100 people, headquartered in Brisbane, California. With a market capitalization of $1.7B, INVA is one of the notable companies in the Healthcare sector.
Innoviva, Inc. (INVA) Stock Rating — Hold (April 2026)
As of April 2026, Innoviva, Inc. receives a Hold rating with a composite score of 52.7/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.INVA ranks #185 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Innoviva, Inc. ranks #4 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
INVA Stock Price and 52-Week Range
Innoviva, Inc. (INVA) currently trades at $23.76. The stock lost $0.44 (1.8%) in the most recent trading session. The 52-week high for INVA is $25.14, which means the stock is currently trading -5.5% from its annual peak. The 52-week low is $16.52, putting the stock 43.8% above its annual trough. Recent trading volume was 859K shares, suggesting relatively thin trading activity.
Is INVA Overvalued or Undervalued? — Valuation Analysis
Innoviva, Inc. (INVA) carries a value factor score of 72/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 15.93x, compared to the Healthcare sector average of 23.63x — a discount of 33%. The price-to-book ratio stands at 1.47x, versus the sector average of 2.75x. The price-to-sales ratio is 4.46x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, INVA trades at 13.10x EV/EBITDA, versus 6.34x for the sector.
Based on these multiples, Innoviva, Inc. appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.
Innoviva, Inc. Profitability — ROE, Margins, and Quality Score
Innoviva, Inc. (INVA) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 9.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 6.6% versus the sector average of -33.1%.
On a margin basis, Innoviva, Inc. reports gross margins of 78.6%, compared to 71.5% for the sector. The operating margin is 33.8% (sector: -66.1%). Net profit margin stands at 23.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 7.9% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
INVA Debt, Balance Sheet, and Financial Health
Innoviva, Inc. has a debt-to-equity ratio of 39.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 14.64x, indicating strong short-term liquidity. Total debt on the balance sheet is $257M. Cash and equivalents stand at $477M.
INVA has a beta of 0.10, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Innoviva, Inc. is 85/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.
Innoviva, Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Innoviva, Inc. reported revenue of $386M and earnings per share (EPS) of $4.02. Net income for the quarter was $108M. Gross margin was 78.6%. Operating income came in at $132M.
In FY 2025, Innoviva, Inc. reported revenue of $411M and earnings per share (EPS) of $4.02. Net income for the quarter was $271M. Gross margin was 74.8%. Revenue grew 14.7% year-over-year compared to FY 2024. Operating income came in at $164M.
In Q3 2025, Innoviva, Inc. reported revenue of $108M and earnings per share (EPS) of $1.30. Net income for the quarter was $90M. Gross margin was 70.1%. Revenue grew 20.4% year-over-year compared to Q3 2024. Operating income came in at $35M.
In Q2 2025, Innoviva, Inc. reported revenue of $100M and earnings per share (EPS) of $1.01. Net income for the quarter was $64M. Gross margin was 82.9%. Revenue grew 0.4% year-over-year compared to Q2 2024. Operating income came in at $49M.
Over the past 8 quarters, Innoviva, Inc. has demonstrated a growth trajectory, with revenue expanding from $100M to $386M. Investors analyzing INVA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
INVA Dividend Yield and Income Analysis
Innoviva, Inc. (INVA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
INVA Momentum and Technical Analysis Profile
Innoviva, Inc. (INVA) has a momentum factor score of 60/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 30/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 3/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
INVA vs Competitors — Healthcare Sector Ranking and Peer Comparison
Comparing INVA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full INVA vs S&P 500 (SPY) comparison to assess how Innoviva, Inc. stacks up against the broader market across all factor dimensions.
INVA Next Earnings Date
No upcoming earnings date has been announced for Innoviva, Inc. (INVA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy INVA? — Investment Thesis Summary
Innoviva, Inc. presents a balanced picture with arguments on both sides. The value score of 72/100 suggests attractive pricing relative to fundamentals. Price momentum is positive at 60/100, suggesting the trend favors buyers. Low volatility (stability score 85/100) reduces downside risk.
In summary, Innoviva, Inc. (INVA) earns a Hold rating with a composite score of 52.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on INVA stock.
We'll email you when stocks you follow change their composite rating.
Execution Benchmarks audit
Revenue Growth
YOY expansion rate
7.9%
Sector: 10.6%
-26% VS SCTR
Gross Margin
Core pricing power
78.6%
Sector: 71.5%
IN LINE
Operating Margin
Operating efficiency
33.8%
Sector: -66.1%
-151% VS SCTR
Net Margin
Bottom-line conversion
23.9%
Sector: -58.7%
-141% VS SCTR
Return on Equity
Equity capital efficiency
9.2%
Sector: -43.5%
-121% VS SCTR
Return on Assets
Asset base utilization
6.6%
Sector: -33.1%
-120% VS SCTR
Debt/Equity
Financial leverage load
39.0%
Sector: 32.0%
-22% VS SCTR
Dividend Yield
Direct cash return
0.0%
Sector: 0.0%
-NaN% VS SCTR
-47%
Price / Sales
4.5x
+169%
Innoviva, Inc. exhibits a 49% valuation premium relative to institutional benchmarks. This represents a potential valuation overextension based on current multiples.
Return on Assets
Efficiency of asset utilization
6.6%
Sector: -33.1%
Gross Margin
Pricing power and cost efficiency
78.6%
Sector: 71.5%
Operating Margin
Core business profitability
33.8%
Sector: -66.1%
Net Margin
Bottom-line profitability
23.9%
Sector: -58.7%
Factor Methodology
The Quality factor evaluates the persistence and magnitude of cash flows. Companies with scores >70 exhibit superior competitive moats and financial resilience through economic cycles.